Raajit Rampal, MD, PhD, on Bone Marrow Recovery in the MANIFEST-2 Trial
By Leah Sherwood, Raajit Rampal, MD, PhD - Last Updated: June 17, 2024Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract titled, “Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the MANIFEST-2 Study: Preliminary Evidence Of Bone Marrow Recovery,” presented at the 2024 European Hematology Association Congress in Madrid, Spain.
Advertisement
Post Tags:EHA 2024
Advertisement
Related Posts
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.